Sponsors

Bay City Capital
Speaker: Lionel Carnot, Senior Investment Professional

Bay City Capital LLC (Bay City Capital) was established in 1997 as an equal partnership between The Craves Group LLC and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry and related activities. Since that date, we’ve managed five investment funds representing approximately $900 million in committed capital, invested in over 55 companies. Four of these funds are life sciences funds, representing approximately $800 million in committed capital. In addition, we serve as the investment advisor for The North American Nutrition and Agribusiness Fund, LP (NANAF), a sector fund, representing $111 million in committed capital.

Bay City Capital seeks to maintain a diversified life sciences portfolio and to invest across all stages of the product lifecycle from discovery through commercialization. Through many years of experience in venture investing, our team has developed a systematic process based on thoughtful selection, comprehensive due diligence and active investment management.

Bay City Capital works closely with our portfolio companies as true partners in their growth, creating value over the long term. We provide ongoing access to a substantial network of industry and academic leaders, experienced advisors, and a significant amount of capital and other resources as needed.

Our Managing Directors, Partners and team of investment professionals have over 200 years of combined experience in operational, financial and scientific roles in the life sciences industry. We have played significant leadership roles in a number of both public and private life science companies, including acting as founders and directors of start-up ventures as well as executive officers of both large cap pharmaceutical and biotechnology companies. The combination of our broad experience in the capital markets and access to a substantial network of scientific and industry expertise gives Bay City Capital a unique perspective and practical approach to creating and maximizing shareholder value.

www.baycitycapital.com

Ernst & Young
Speakers: Patrick Flochel, Partner
Heinrich Christen, Partner, Industry Leader Medtech

Expanding Horizons
Ernst & Young helps organizations manage their business risks, form the right alliances, access funding and gain insight into the market and regulatory environment of today's dynamic Medtech Industry.

Ernst & Young provides comprehensive services and global coverage for Medtech companies. Our team delivers advice and services covering business strategy to operational support, security to due diligence backed by an in-depth understanding of your company – and the market in which you compete.

A Medtech / Life Sciences Global Network is in place to ensure that your Ernst & Young team has:
• the latest industry specific insights
• a detailed understanding of industry risks
• specialized resources around the world to address unique Medtech issues

The Market is Moving
The Medtech industry is fast moving. Current trends include:
• increased M&A activity due to the fact that companies are focusing on core competencies
• suppliers will have fewer, but more powerful customers
• sales and marketing are becoming more critical to success
• Switzerland will remain a prime location for high value production and for research and development as well as a preferred location for corporate headquarters

Our Track Record
Ernst & Young has built a strong market position and has a reputation as an innovative business advisor to many leaders in the Medtech industry. We provide cutting edge advice to the Life Sciences industry (Pharma, Medtech and Biotech industries) worldwide. In Switzerland we work with most of the leading Medtech companies.

The Team You Need
Ernst & Young Switzerland has a team of 10 professionals who focus on the Medtech industry. The Medtech Team can then, depending upon the clientÕs needs, bring in an extensive array of specialists to work with the client.

Thought Leadership
To add value for our clients Ernst & Young conducts various Medtech studies and shares the results along with Ernst & Young’s perspective with clients. In addition, newsletters and conferences are used to share information about current industry developments and accounting issues. Current studies include:

The Swiss Medtech Report 2005 – s study is the first comprehensive study about the Swiss Medtech industry, aimed primarily at foreign investors and clients. It shows that this growing industry with approx. 500 companies, 40,000 employees and R&D expenditures of over 500 Mio USD has some significant challenges ahead.

www.ey.com

Global Life Science Ventures
Speaker: Dr Peter Reinisch, Partner

A brief overview of Global Life Science Ventures

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups originating from universities, scientific institutions or industry, but will also invest in selected later-stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds greater than EUR 200 million. With two locations in Germany and Switzerland, GLSV acts as one team with a global perspective.

An industry-born team. GLSV has established a strong investment team (currently 7 professionals) and a network of advisors with many years of complementary experience in the life science industry. The expertise of the team ranges from industrial experience in molecular biology, immunology, diagnostics, pharmaceuticals and medical devices to marketing, senior level strategic business development, finance and administration.

Proven track record. Over the years, GLSV has achieved a sound track record through discerning investments in high-potential companies. After registration of the original fund GLS I in 1996, the available capital of Euro 66 million has been invested in first and follow-on financing rounds of 18 ventures active in the life sciences. The positive development of the first fund has been highlighted by successful exits of seven companies through IPO and merger & acquisition transactions and also included a number of board seat representations, several of which were at chairman level.

In 2002, GLSV closed its second fund GLSV II of Euro 143 million, which met the projected target by more than doubling the size of its predecessor. All existing investors renewed their financial commitment to the fund. GLSV II has been invested in 16 companies so far, four of which have already achieved public listings and one an exit through a trade sale. GLSV II is financing further promising companies in the life sciences that address significant unmet medical needs. The new investments meet GLSV’s established criteria for a balanced portfolio across different industry sectors, development stages and geography.

Pro-active syndicate partner. GLSV offers its investees access to the capital, experience and networks of a group of international venture capitalists that invest in the life sciences on a global scale. Syndicate partnerships are made with funds whose investment criteria and philosophy match those of GLSV. A global perspective is provided by syndicate partnerships with leading US-based funds. The GLSV portfolio includes companies active in many areas of the life sciences ranging from biopharmaceuticals, cancer, immunology, vaccines and genomics to diagnostics, medical devices and healthcare services.

Switzerland
GLSV AG
Postplatz 1, P.O. 626
CH – 6301 Zug
Tel +41 (0)41 727 19 40
Fax +41 (0)41 727 19 45

Germany
GLSV GmbH
Von-der-Tann-Str. 3
D – 80539 München
Tel +49 (0)89 288 151 0
Fax +49 (0)89 288 151 30

www.glsv-vc.com

Katan Associates
Speaker: Stan Yakatan, Chairman

Your Global Capitalization Partner
Katan Associates is a global advisory organization that provides capitalization strategies and a broad range of services to high growth, highly innovative life sciences companies, biotechnology firms and biomedical enterprises.

Based in the world’s leading centers for biotechnology and biomedicare, Katan Associates brings together specialists from a diverse range of corporate and commercial backgrounds to advise firms on long term growth and capitalization solutions.

Katan Associates focuses on five core areas of specialization in helping firms achieve their business growth.

Strategy Formulation
International Business Development
Investment Banking / Venture Capital
Government and Industry Advisory
Mergers and Acquisitions

Katan provides businesses and management teams with the tools and the infrastructure to grow and expand their business.

To find out more, please visit our website at www.katanassociates.com

Or contact Seth Yakatan, Partner, at 323.356.6321 or seth@katanassociates.com

Novartis Venture Fund
Speaker: Reinhold Ambros, Managing Director, Novartis Venture Fund

Novartis AG, a holding company organized under Swiss law, owns directly or indirectly all Novartis companies worldwide.

The Novartis Group is divided into two divisions: Pharmaceuticals and Consumer Health. The Pharmaceuticals Division is organized into five business units: Primary Care, Oncology, Transplantation, Mature Products, and Optalmics. The six business units of the Consumer Health Division are: Generics, Over-the-Counter self medication (OTC), Animal Health, Medical Nutrition, Infant & Baby, and CIBA Vision.

The Novartis Pharamaceuticals Division is a world leader in discovery, development, manufacture, and marketing of prescription medicines. Its goal is to provide a broad portfolio of innovative, effective and safe products and services to patients through healthcare professionals around the world. This goal is supported by a dedicated organization operating in more than 140 countries through approximately 80 affiliates.

www.novartis.com

SWX Swiss Exchange
Speakers: Heinrich Henckel, Chief Executive Officer
Yvonne Wegmann, Vice President, Head of Issuers & Investor Relations

The SWX Swiss Exchange ranks among the world’s most technologically advanced securities exchanges. Backed by the strength of Switzerland’s financial marketplace, it resolutely pursues an internationally oriented strategy. In transnational collaboration with partner organisations, the SWX Swiss Exchange provides first-rate securities exchange services to all parties involved. Not only is its broad product palette a convincing factor in this regard, but also its fully integrated and totally automated trading, clearing and settlement system that remains unique in the world.

The SWX Swiss Exchange offers innovative, international companies access to the Swiss capital market. A public placement of securities in one of its trading segments affords companies a high degree of global visibility among investors. An initial public offering in Switzerland is an attractive opportunity for companies to raise equity capital, especially those in the life science, IT and micro- and nanotechnology industries.

SWX Swiss Exchange
Christoph Schuler
Relationship Manager Issuers & Investor Relations
Selnaustrasse 30
8021 Zürich
Schweiz
T +41(0)58 854 23 59
F +41(0)58 854 22 40
E-mail: ipo@swx.com

www.swx.com

Techno Venture Management
Speaker: Dr Alexandra Goll, General Partner

Techno Venture Management (TVM), founded in 1983, is one of the first venture capital funds formed in Germany, and a leader in transatlantic operations. The German-U.S. venture capital company has offices in Munich and Boston. For many years, TVM has focused on information technology and life sciences, high growth sectors where innovation, effective management and sound financial backing have enormous impact on company growth. TVM funds have made investments in 200 technology companies in Europe and the United States. A pivotal objective is to create transnational businesses that enjoy access to science, management talent and capital on both sides of the Atlantic.